Biohaven Ltd. (NYSE: BHVN) has announced the topline data from its Study BHV4157-206-RWE (NCT06529146), which evaluated the efficacy of troriluzole in patients with Spinocerebellar Ataxia (SCA). The study, conducted in consultation with the U.S. Food and Drug Administration (FDA), aims to address the unmet needs in SCA treatment.
Troriluzole: A Novel Approach to Glutamate Modulation
Troriluzole, a new chemical entity, functions as a third-generation prodrug that modulates glutamate, the primary excitatory neurotransmitter in the human body. Its mechanism of action involves reducing synaptic glutamate levels by increasing glutamate uptake from the synapse. This is achieved by augmenting the expression and function of excitatory amino acid transporters on glial cells, which play a crucial role in clearing glutamate from the synapse. Troriluzole is being explored for various diseases associated with excessive glutamate.
Conference Call Details
Biohaven will host a conference call and webcast on Monday, September 23, 2024, at 8:30 a.m. Eastern Time, to discuss the topline data. Interested parties can access the live event through the Investor Relations section of Biohaven's website. Participants can also join the conference call via telephone by registering in advance to receive a dial-in number and unique PIN.
Biohaven's Broader Pipeline
Biohaven is a biopharmaceutical company focused on discovering, developing, and commercializing treatments in immunology, neuroscience, and oncology. The company's pipeline includes programs targeting Kv7 ion channel modulation for epilepsy and mood disorders, extracellular protein degradation for immunological diseases, TRPM3 antagonism for migraine and neuropathic pain, TYK2/JAK1 inhibition for neuroinflammatory disorders, myostatin inhibition for neuromuscular and metabolic diseases, and antibody recruiting bispecific molecules and antibody drug conjugates for cancer.
